

REMARKS


Claims 1-43 have been rewritten as claims 44-54 to conform with US practice. There is no new matter added, and entry of the amendment is respectfully requested.

Applicants also enclose a paper copy and a computer readable form of a Sequence Listing. The content of the paper copy and of the computer readable form is the same. The specification has been amended to provide SEQ ID NOS for the sequences disclosed therein. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 10, 2006


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097